Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis

Figures & data

Table 1. Demographic characteristics of study participants with CF and healthy siblings.

Characteristic	n (%)
Health Status	All	Cystic Fibrosis	Healthy
n/N (%)	76	59/76 (78%)	17/76 (22%)
Age (years)
Range	2–19	2–19	4–19
Mean (SD)	10.20 (4.98)	10.25 (5.07)	9.99 (4.78)
Median	10.00	10.80	9.10
Interquartile range	(5.65, 14.20)	(5.40, 14.50)	(6.60, 12.50)
Sex
Female	39 (51%)	28 (47%)	11 (65%)
Study site
BC Children's Hospital	47 (62%)	30 (51%)	17 (100%)
Montréal Children's Hospital	29 (38%)	29 (49%)	0 (0%)
Vaccinated last year
LAIV	29 (38%)	29 (49%)	0 (0%)
TIV	43 (57%)	29 (49%)	14 (82%)
None	4 (5%)	1 (2%)	3 (18%)

Figure 1. Results of the sensitivity analyses estimating the effect of measurement error in the diagnostic assays used to ascertain exposure (D0-NIRV) and outcome (detection of influenza RNA). The point and line edges represent the mean, 2.5^th and 97.5^th percentiles of the posterior distribution, respectively.

Figure 2. Proportion of subjects with any influenza virus RNA detection (either type (A)and/or B), by study day, cystic fibrosis (CF) status and non-influenza respiratory virus (D0-NIRV) detection status on day 0 (n_{CF, D0-NIRV+} = 18, n_{CF, D0-NIRV-} = 40, n_{non-CF, D0-NIRV+} = 4, n_{non-CF, D0-NIRV-} = 13).

Table 2. Summary of influenza detection after vaccination with LAIV in study cohort (days 1–7 of follow-up).

	Respiratory Virus Panel Day 0 Result*
Detection Duration	Positive (n = 22)	Negative (n = 52)	Difference‡ (95% CrI)
Subjects with any influenza virus detected throughout follow-up, % (n/N)	59% (13/22)	75% (39/52)	16% (−7, 39)
Total detection episodes*	14	44	30 (15, 45)
Duration	9	15	6 (−3, 16)
One day (sample)	2	13	11 (4, 19)
Two consecutive samples	1	8	7 (2, 14)
Three consecutive samples	2	8	6 (0, 13)
Four consecutive samples
Average duration of detection, mean (95% CrI)	1.71 (1.10,2.47)	2.21 (1.79,2.67)	0.49 (−0.37, 1.26)

* Day 0 samples missing for 2/76 participants.

‡ Negative – Positive

* An episode of virus detection is defined as a stretch of consecutive samples positive for influenza virus genetic material.